Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
Recruiting · NCT07356050 · Observational (researchers observe without assigning treatment) · Lead sponsor: Children's Hospital Medical Center, Cincinnati
View the official record on ClinicalTrials.gov →What this trial is about
The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
Who can take part
Age range
6 Months to 6 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Participants with confirmed Sickle Cell Disease.
- Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
- Willing and able to provide informed consent
- Ability to comply with study related evaluations and follow-up visits.
Exclusion criteria
- \. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.
Where it is running
3 locations listed across 1 US state.
- Cincinnati Children's Hospital Medical Center - Cincinnati, Ohio, United States
- Bugando Medical Centre - Mwanza, Tanzania
- Korle Bu Teaching Hospital - Accra, Ghana, Ghana